QuidelOrtho R&D Spending Growth & History (QDEL)
QuidelOrtho's r&d spending was $186.2M for fiscal 2025.
View full QuidelOrtho company overviewQuidelOrtho annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $186.2M | −$32.5M | −14.86% |
| 2024 | 2024-12-29 | $218.7M | −$26.3M | −10.73% |
| 2023 | 2023-12-31 | $245.0M | $57.1M | +30.39% |
| 2022 | 2023-01-01 | $187.9M | $92.2M | +96.34% |
| 2021 | 2022-01-02 | $95.7M | $11.4M | +13.52% |
| 2020 | 2021-01-03 | $84.3M | — | — |
QuidelOrtho quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $48.7M | $3.0M | +6.56% |
| Q1 2026 | 2026-03-29 | $44.9M | −$8.3M | −15.60% |
| Q4 2025 | 2025-12-28 | $45.8M | −$1.5M | −3.17% |
| Q3 2025 | 2025-09-28 | $41.5M | −$14.4M | −25.76% |
| Q2 2025 | 2025-06-29 | $45.7M | −$10.6M | −18.83% |
| Q1 2025 | 2025-03-30 | $53.2M | −$6.0M | −10.14% |
| Q4 2024 | 2024-12-29 | $47.3M | −$11.5M | −19.56% |
| Q3 2024 | 2024-09-29 | $55.9M | −$5.6M | −9.11% |
| Q2 2024 | 2024-06-30 | $56.3M | −$6.1M | −9.78% |
| Q1 2024 | 2024-03-31 | $59.2M | −$3.1M | −4.98% |
| Q4 2023 | 2023-12-31 | $58.8M | −$2.9M | −4.70% |
| Q3 2023 | 2023-10-01 | $61.5M | −$4.1M | −6.25% |
| Q2 2023 | 2023-07-02 | $62.4M | $28.2M | +82.46% |
| Q1 2023 | 2023-04-02 | $62.3M | $35.9M | +135.98% |
| Q4 2022 | 2023-01-01 | $61.7M | — | — |
| Q3 2022 | 2022-10-02 | $65.6M | $41.9M | +176.79% |
| Q2 2022 | 2022-07-03 | $34.2M | $11.6M | +51.33% |
| Q1 2022 | 2022-04-03 | $26.4M | — | — |
| Q3 2021 | 2021-10-03 | $23.7M | — | — |
| Q2 2021 | 2021-07-04 | $22.6M | — | — |
QuidelOrtho r&d spending trends
Over the last five fiscal years, QuidelOrtho's r&d spending increased from $84.3M to $186.2M, a change of $101.9M. The latest reported quarter, Q2 2026, shows $48.7M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review QuidelOrtho source filings ↗